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Several million people are exposed to dioxin and dioxin-like
compounds, primarily through food consumption. Skin lesions
historically called ‘‘chloracne’’ are the most specific sign of
abnormal dioxin exposure and classically used as a key marker in
humans. We followed for 5 years a man who had been exposed to
the most toxic dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), at a single oral dose of 5 million-fold more than the
accepted daily exposure in the general population. We adopted
a molecular medicine approach, aimed at identifying appropriate
therapy. Skin lesions, which progressively covered up to 40% of
the body surface, were found to be hamartomas, which developed
parallel to a complete and sustained involution of sebaceous
glands, with concurrent transcriptomic alterations pointing to the
inhibition of lipid metabolism and the involvement of bone
morphogenetic proteins signaling. Hamartomas created a new
compartment that concentrated TCDD up to 10-fold compared
with serum and strongly expressed the TCDD-metabolizing
enzyme cytochrome P450 1A1, thus representing a potentially
significant source of enzymatic activity, which may add to the
xenobiotic metabolism potential of the classical organs such as the
liver. This historical case provides a unique set of data on the
human tissue response to dioxin for the identification of new
markers of exposure in human populations. The herein discovered
adaptive cutaneous response to TCDD also points to the potential
role of the skin in the metabolism of food xenobiotics.
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Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) is the
most potent of a large number of industrial-era halogenated
polyaromatic hydrocarbon pollutants, including other dibenzo-p-
dioxins, dibenzofurans, and certain polychlorinated biphenyls.
Human populations are exposed to low levels of dioxin and
dioxin-like compounds, primarily through food consumption
(Connor et al., 2008; Schecter et al., 1999). The risk
characterization of dioxin exposure remains difficult to establish,
although it is an issue that broadly affects important public health
policy decisions (Gies et al., 2007; Steenland et al., 2001). Thus,
chronic exposure to low/moderate doses of dioxin may be
involved not only in the classic dioxin toxicity in some
genetically predisposed individuals (IARC Monograph, 1997;
Aylward et al., 2005) but also in the newly identified role of
these compounds in autoimmunity (Brembilla et al., 2011;
Marshall and Kerkvliet, 2010; Ramirez et al., 2010).
In humans, skin lesions called ‘‘chloracne’’ are the most
visible and consistent response to dioxin exposure and therefore
play the role of a sentinel sign for toxicity (Caputo et al., 1988).
The mechanism by which chloracne appears was not previously
known and its diagnostic value is not straightforward, especially
in mild and sporadic cases, which could still relate to significant
exposure (Passarini et al., 2010). A robust indicator that would
trigger specific ecotoxicology diagnostic processes is lacking; in
the current situation, it is likely that many cases have not been
recognized (Saurat and Sorg, 2010).
We have previously reported on the TCDD poisoning in
Victor Yushchenko with identification and measurement of
TCDD metabolites (Sorg et al., 2009). The maximum accepted
daily dose exposure in human is 4 pg/kg, and this patient
received a single dose of 20 lg/kg.
With the approval of the patient to release peer-reviewed
scientific information on his case, we now report on a set of
data that has never been obtained in humans and helps define
the phenotype of the dioxin-induced skin pathology.
MATERIALS AND METHODS
Clinical specimens. Skin sampling was performed under general anesthe-
sia during therapeutic procedures.
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Histopathological and immunohistochemical evaluation. Sections were
cut from formalin-fixed, paraffin-embedded skin biopsy specimens and stained
with hematoxylin and eosin. Cytochrome P450 (CYP) 1A1 immunohisto-
chemical analysis was performed with the use of an immunoperoxidase
technique according to standard procedures (Lebeau et al., 2005).
Dioxin analysis. TCDD was determined in lipid extracts from serum and
skin samples using gas chromatography with high-resolution mass spectrom-
etry as previously described (Sorg et al., 2009).
Imaging and volumetric analysis. Radiologic follow-up included high-
resolution magnetic resonance (MR) imaging examinations of the face and head
at 1.5 T and total body positron emission tomography/computed tomography
(PET/CT) exams. The acquired MR and PET/CT data obtained for diagnostic,
pretherapeutic, and follow-up purposes formed the basis of our volumetric
analysis. The total skin volume and the combined volume of all hamartomatous
skin lesions in the examined area were calculated separately using
commercially available software according to the manufacturers’ instructions
(GE Healthcare Advantage Windows). Individual skin lesions on each slice
were defined by manual contouring, and appropriate thresholding was used to
determine total skin volume. The software was used to generate three-
dimensional representations of the calculated total skin volume and of the
calculated volume of all hamartomatous lesions.
Gene expression analysis. Total RNA extracts from skin samples (face) of
the patient and four healthy Caucasian men matched for age, sex, race, and site
of sampling were prepared as previously reported (Sorg et al., 2008). RNA
quality was assessed using an Agilent 2100 Bioanalyzer with an RNA 6000
Nano LabChip kit. We generated a hybridization mixture containing 15 lg of
biotinylated complementary RNA and hybridized it to GeneChip HG U133
Plus 2.0 according to manufacturer’s instructions (Affymetrix). To identify
differentially expressed transcripts, comparisons were carried out after
normalization with the Affymetrix GCOS 1.2 (MAS5) software.
Bioinformatic analysis. Responsive elements for genes corresponding to
differentially expressed transcripts were searched with the University of
California—Santa Cruz Genome Browser (http://genome.ucsc.edu/, March
2006 [NCBI36/hg18] assembly) in the Transcription Factor Binding Sites
Conserved Track (Fujita et al., 2010) and Gene2Promoter and MatInspector
from Genomatix software (www.genomatix.de) (Cartharius et al., 2005). For
most of the tested genes, the same responsive elements were found with both
resources.
RESULTS
Dioxin-Induced Skin Lesions Progress over Months while
Internal Organs Heal
A few hours after dinner in Kiev on 5 September 2004, a 50-
year-old male patient suddenly became severely ill. Hospital
work-up revealed gastritis, colitis with multiple ulcers, hepatitis,
and pancreatitis, all compatible with poisoning by an ‘‘unknown
substance’’ because testing for thallium, arsenic, antimony,
mercury, and lead was negative (Ryan, 2011). Severe facial
edema appeared 2 weeks after the poisoning (W2 a.p.). By W6
a.p., the digestive tract symptoms had improved (Fig. 1).
However, severe bilateral lower limb neuropathic pain appeared,
and electroneuromyography confirmed that this was caused by
small fiber peripheral neuropathy (The organs and systems
involved, other than the skin, are just cited here. Each will be
fully addressed in future publications when the mechanism has
been better analyzed by appropriate ongoing data analysis.).
Facial involvement worsened with diffuse nodular lesions on an
edematous background, sparing of the periocular zone, but
major involvement of the ears and retroauricular folds (Figs. 2A
and 2B). The basic skin lesions were small nodules (Fig. 2C),
FIG. 1. Evolution of the dioxin disease. Chronology of organ involvement a.p. The peak of skin involvement is delayed as compared with the other organs,
and skin lesions show a longer and chronic course.
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with rapid growth into cysts that developed severe painful
inflammation. These lesions were clinically very similar to those
of severe nodulocystic acne (Plewig and Kligman, 1993). By
W10 a.p., a few scattered cystic lesions had appeared on the
body, but it was not until 9 months (M9) a.p. that lesions became
widespread over the entire body, including the limbs, with
a peak clinical manifestation at M11 a.p (Fig. 1). Palms and
soles were spared and have remained so for the subsequent years
of follow-up. Only a few lesions occurred in the axillary and
inguino genital folds.
Skin Lesions Are Hamartomas
The data are based on 52 skin specimens taken over M43,
which showed consistently identical aspects. The key
features were ‘‘structure loss’’ and ‘‘structure gain,’’ with
preservation of other normal skin structures, thereby
compatible with hamartomas (http://en.wikipedia.org/wiki/
Hamartoma) (Albrecht, 1904).
The structure loss was the disappearance of the sebaceous
glands. This loss occurred to a striking extent: on 252
histological slides studied, not a single sebaceous gland was
observed (a very conservative estimate of normal numbers
would be from 500 to 4500 sebaceous glands observed on 252
slides) (Montagna, 1963).
The structure gain was the appearance of cystic lesions with
epithelial walls showing epidermal-like differentiation with the
expected distribution of epidermal keratins (not shown). These
lesions (Figs. 3A–C) were either superficial with an open
comedo-like aspect or extending much deeper in the dermis,
hence resembling infundibular cysts (Plewig and Kligman,
1993), but with the following distinct characteristics: (1)
mantle-like columnar epithelial downgrowths, showing high
proliferative activity (Ki67-positive cells, not shown), puta-
tively giving birth to new cysts, resulting in branching cystic
figures with downward growth (Figs. 3A–C) and (2) focal
expression of CYP1A1, the major dioxin-metabolizing CYP
enzyme, in the epithelial walls of the cystic lesions as shown by
immunohistochemistry (Figs. 3A and 3C).
Gene Expression in the Skin
Gene expression as monitored by whole-genome micro-
arrays analysis was strongly altered in this hamartomatous skin,
as compared with age, sex, race, and site of sampling skin
specimens taken in healthy subjects (Table 1).
The majority of differentially expressed genes were re-
pressed: thus, when a cutoff of more than twofold was
considered for the analysis of skin samples taken at M5 a.p.,
530 genes were found to be differentially expressed, 63% of
which were repressed.
Table 1 shows a more stringent sorting, with only the genes
downregulated more than 10-fold and those upregulated more
than threefold in skin samples taken M5 a.p.. Table 1 includes in
addition (1) the key genes of the aryl hydrocarbon receptor (AhR)
dioxin signaling pathway, whatever their modulation, and (2)
another transcriptome performed M11 a.p. in order to evaluate
the permanence of the altered gene expression, which was found
to be quite consistent (see Table 1, fold changes M5 and M11).
Among the genes known to be involved in AhR/dioxin
pathway, the most induced were CYP1A1, CYP1B1, CYP1A2,
and the aryl hydrocarbon receptor repressor (AhRR), whereas
the AhR itself, its chaperones heat shock protein 90 and
prostaglandin E synthase 3 (p23), as well as aryl hydrocarbon
receptor nuclear translocator/HIFb genes were not differen-
tially expressed. Real time PCR analysis for AhR, AhRR,
CYP1A1, and CYP1A2, performed on independent samples
dissected at the same time, confirmed these results (data not
shown). This indicates that a strong and sustained induction of
the AhR pathway does occur in the skin lesions and provides,
for the first time in humans, information on the relative
expression of each player under high dioxin exposure.
The most represented structural/functional family of genes
differentially expressed was related to lipid metabolism. In this
family, all genes were repressed except phospholipase A2
group IIA, which was induced threefold. The repressed genes
FIG. 2. Representative pictures of the skin lesions. (A) Facial, auricular,
and retroauricular nodular lesions on an edematous background at month 4 a.p.
(B) Axial, high-resolution T2-weighted MR image at the level of the mid face
showing many hamartomas located in the dermis, on the cheek, the ear lobe,
and retroauricular fold. Note variable size of the cysts, the largest being located
in the ear lobe. Some cysts extend into the subcutaneous fat. (C) Per-operative
aspect of the hamartomas on the ear lobule at month 4 a.p.
FIG. 3. Histological analyses of the skin lesions. (A) Photomicrograph of
a skin sample from the retroauricular area stained with hematoxylin-eosin (upper
part) showing the dermal distribution of the hamartomas and the absence of
sebaceous glands and (lower part) reacted with anti-CYP1A1 showing the focal
expression of the enzyme in the hamartomas (scanning magnification; monoclonal
anti-CYP1A1 antibody, Santa Cruz Biotechnology, diluted 1:50). (B) Photomi-
crograph of one of the hamartoma showing mantle-like columnar epithelial
downgrowths (Hematoxylin-eosin, original magnification: X20). (C) Immunohis-
tochemical staining of CYP1A1 in a hamartoma. Original magnification: X20.
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TABLE 1
Fold Changes of the Patient Compared with Means of Controls in Whole-Genome Microarray Gene Expression Analysis of Skin
Samples of the Face Taken at Months 5 and 11 a.p. in (1) Genes of the Dioxin Signaling Pathway, (2) Genes Downregulated More than
10-fold, and (3) Genes Upregulated More than Threefold
Fold change
Structural/functional family Affymetrix ID Symbol Description 5 months 11 months
Dioxin signaling pathway 205749_at CYP1A1 Cytochrome P450, family 1, subfamily A,
polypeptide 1
171.9 114.3
202436_s_at CYP1B1 Cytochrome P450, family 1, subfamily B,
polypeptide 1
9.8 4.7
207608_x_at CYP1A2 Cytochrome P450, family 1, subfamily A,
polypeptide 2
6.7 3.5
229354_at AhRR Aryl hydrocarbon receptor repressor 3.9 4.2
230619_at ARNT Aryl hydrocarbon receptor nuclear
translocator
1.1 1.3
200599_s_at HSP90B1 Heat shock protein 90 kDa beta (Grp94),
member 1
1.1 0.7
201782_s_at AIP Aryl hydrocarbon receptor interacting protein 1.0 0.8
200627_at PTGES3 Prostaglandin E synthase 3 (cytosolic) 0.9 0.6
202820_at AhR Aryl hydrocarbon receptor 0.8 0.9
Lipid metabolism 203649_s_at PLA2G2A Phospholipase A2, group IIA 3.1 1.9
219429_at FA2H Fatty acid 2-hydroxylase 4.9 24.7
210452_x_at CYP4F2 Cytochrome P450, family 4, subfamily F,
polypeptide 2
6.5 8.8
205822_s_at HMGCS1 3-Hydroxy-3-methylglutaryl-CoA synthase 1 8.8 20.8
219131_at UBIAD1 UbiA prenyltransferase domain containing 1 10.5 17.0
221561_at SOAT1 Sterol O-acyltransferase 1 11.0 45.9
205404_at HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1 13.7 17.4
206465_at ACSBG1 Acyl-CoA synthetase bubblegum family
member 1
15.8 19.3
221142_s_at PECR Peroxisomal trans-2-enoyl-CoA reductase 16.1 28.1
232428_at MOGAT2 Monoacylglycerol O-acyltransferase 2 22.0 107.1
208962_s_at FADS1 Fatty acid desaturase 1 29.0 33.4
234513_at ELOVL3 Elongation of very long chain fatty acids-like
3
34.5 110.7
239108_at FAR2 Fatty acyl CoA reductase 2 38.4 45.8
205029_s_at FABP7 Fatty acid–binding protein 7 43.2 6.8
1553062_at MOGAT1 Monoacylglycerol O-acyltransferase 1 46.1 165.3
233126_s_at OLAH Oleoyl-ACP hydrolase 54.0 75.9
210576_at CYP4F8 Cytochrome P450, family 4, subfamily F,
polypeptide 8
66.7 352.2
1555416_a_at ALOX15B Arachidonate 15-lipoxygenase type I 70.6 1002.2
205942_s_at ACSM3 Acyl-CoA synthetase medium-chain family
member 3
75.0 138.1
1560507_at AWAT1 Acyl-CoA wax alcohol acyltransferase 1 79.4 324.8
202218_s_at FADS2 Fatty acid desaturase 2 114.9 114.4
204515_at HSD3B1 Hydroxy-delta-5-steroid dehydrogenase, 3
beta- and steroid delta-isomerase 1
129.9 1066.0
229476_s_at THRSP Thyroid hormone responsive 2769.7 250.1
Morphogenesis 240509_s_at GREM2 Gremlin 2 6.3 2.2
229404_at TWIST2 Twist homolog 2 3.2 1.9
226944_at HTRA3 High temperature requirement factor A serine
peptidase 3
3.2 1.3
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TABLE 1—Continued
Fold change
Structural/functional family Affymetrix ID Symbol Description 5 months 11 months
Extracellular matrix 206026_s_at TNFAIP6 Tumor necrosis factor alpha-induced protein
6
5.2 2.4
202998_s_at LOXL2 Lysyl oxidase-like 2 4.2 1.6
206093_x_at TNXB Tenascin X 4.1 2.0
202888_s_at ANPEP Alanyl (membrane) aminopeptidase 3.5 1.3
209758_s_at MFAP5 Microfibrillar associated protein 5 3.5 1.4
202766_s_at FBN1 Fibrillin 1 3.3 1.8
220783_at MMP27 Matrix metallopeptidase 27 3.1 1.5
203184_at FBN2 Fibrillin 2 3.1 3.7
221731_x_at VCAN Versican 3.1 2.1
Inflammation 219837_s_at CYTL1 Cytokine-like 1 5.9 6.2
220351_at CCRL1 Chemokine (C-C motif) receptor-like 1 4.1 3.0
220088_at C5AR1 Complement component 5a receptor 1 3.5 2.2
213716_s_at SECTM1 Secreted and transmembrane 1 3.1 3.0
Solute carrier family 225491_at SLC1A2 Solute carrier family 1 3.2 1.7
220435_at SLC30A10 Solute carrier family 30, member 10 10.3 144.7
223605_at SLC25A18 Solute carrier family 25 (mitochondrial
carrier), member 18
11.2 6.4
205769_at SLC27A2 Solute carrier family 27 (fatty acid
transporter), member A2
13.7 9.3
222071_s_at SLCO4C1 Solute carrier organic anion transporter
family, member 4C1
20.2 11.6
205380_at PDZK1 PDZ domain containing 1 40.5 131.4
206143_at SLC26A3 Solute carrier family 26, member 3 59.3 30.7
Various enzymes 206561_s_at AKR1B10 Aldo-keto reductase family 1, member B10 4.3 2.0
1555745_a_at LYZ Lysozyme 3.1 2.2
206209_s_at CA4 Carbonic anhydrase IV 3.1 2.0
209522_s_at CRAT Carnitine acetyltransferase 12.1 11.7
227055_at METTL7B Methyltransferase like 7B 13.5 7.6
208383_s_at PCK1 Phosphoenolpyruvate carboxykinase 1 14.3 9.1
204836_at GLDC Glycine dehydrogenase 27.6 50.9
220801_s_at HAO2 Hydroxyacid oxidase 2 30.6 58.5
205221_at HGD Homogentisate 1,2-dioxygenase 38.5 11.5
220507_s_at UPB1 Ureidopropionase, beta 69.7 133.8
204997_at GPD1 Glycerol-3-phosphate dehydrogenase 1 86.2 157.8
239929_at PM20D1 Peptidase M20 domain containing 1 136.7 128.1
Miscellaneous 205513_at TCN1 Transcobalamin 21.9 1.8
1562337_at OR7D2 Olfactory receptor, family 7, subfamily D,
member 2
5.2 5.1
228335_at CLDN11 Claudin 11 5.2 3.1
220784_s_at UTS2 Urotensin 2 4.9 14.9
239492_at SEC14L4 SEC14-like 4 10.2 12.6
203001_s_at STMN2 Stathmin-like 2 13.9 10.6
201625_s_at INSIG1 Insulin-induced gene 1 16.6 21.2
213780_at TCHH Trichohyalin 16.7 1.8
214624_at UPK1A Uroplakin 1A 18.7 99.7
229095_s_at LIMS3 LIM and senescent cell antigen-like domains
3-like
27.2 51.5
210419_at BARX2 BARX homeobox 29.8 2.7
203400_s_at TF Transferrin 74.4 57.8
214240_at GAL Galanin prepropeptide 105.3 473.3
233052_at DNAH8 Dynein, axonemal, heavy chain 142.6 153.7
Note. Microarray Database: http://www.ebi.ac.uk/arrayexpress/. Experiment Name: Dupond: Transcriptional Analysis of a Clinical Case of Acute Dioxin
Poisoning; ArrayExpress Accession: E-MTAB-617. Reviewer’s User Account—Username: Reviewer_E-MTAB-617, Password: ehhary9g.
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included some genes specifically involved in sebum lipid
metabolism.
AhR-responsive elements were identified in the promoter
regions of FADS2, AWAT1, ELOVL3, ALOX15B, and sterol O-
acyltransferase 1 genes.
The differentially expressed genes involved in tissue renewing
may relate to hamartomas formation. Among the induced genes,
gremlin 2 and high temperature requirement factor A serine
peptidase 3, which encode for antagonists of the bone
morphogenic protein family (BMP), may be highly relevant to
the process of hamartomas formation (Sneddon et al., 2006).
Most of the differentially expressed genes from structural/
functional families shown in Table 1 as ‘‘extracellular matrix’’
and ‘‘inflammation’’ were induced, which was expected from
the clinicopathological but does not suggest a specific pattern.
The solute carrier family genes were all strongly repressed
except one. This family encodes proteins involved in the
trafficking of many compounds including fatty acids, cholesterol,
conjugated steroids, eicosanoids, peptides, and numerous drugs.
That so many genes of this family/function were repressed
suggests that specific studies are indicated for analyzing the link
with dioxin toxicity. This also applies to the differentially
expressed genes in the functional family of metabolism.
Dioxin Concentrates in the Skin Lesions: The Emergence of
a New Compartment
Figure 4 shows the progressive decrease of TCDD levels in
the serum, which contrasts with an increase of TCDD levels in
the skin lesions that reaches a peak at M11 a.p. At that time,
TCDD concentration in skin lesions was 10-fold that of serum.
This indicates that the skin lesions do constitute a significant
novel compartment, which we calculated to be for the face 482
cm3 or 68.5% of the total skin volume (704 cm3) (Fig. 5).
Because at M11 a.p. 40% of the total body skin surface was
covered with hamartomatous lesions, it can be estimated that
during the peak manifestation of the cutaneous disease, the
total volume of the hamartomatous compartment could have
reached 6400 cm3 for the entire body, containing about 35 lg
TCDD, i.e., 2% of the initial total body burden.
Synopsis of Therapeutical Measures Derived from
Observations
We initially observed that any incisional approach resulted
in dystrophic healing, which we found to be a dioxin-induced,
very fast skin healing response (Barouti et al., 2009). With this
important limiting feature to incisional skin intervention, we
found that mechanical dermabrasion and multiple micro punch
extraction/aspiration techniques yielded very quick healing
(again due to the mechanism cited above) and were
cosmetically still satisfactory. These methods allowed both
significant pain relief from inflammation and extraction of large
amounts of dioxin-rich hamartomatous lesions. A total of 26
procedures were performed on the whole-body skin surface
under general anesthesia, from M4 to M46 a.p.
Compassionate use of tumor necrosis factor a (TNF-a) blockade
was considered because non-steroidal anti-inflammatory drugs and
systemic steroids were not effective. The patient received three
infusions of infliximab but because of intolerance was then switched
to adalimumab, which was given for M18 (M16th to M34th a.p.).
FIG. 4. Kinetics of TCDD showing the concentration of dioxin in the skin
lesions: the emergence of a new compartment. Despite a progressive decrease
in serum TCDD from months 3 to 15 a.p., there was a concomitant increase of
TCDD concentration in skin, while the surface of skin involvement spread. For
each parameter, the results are expressed as the percentage of the maximum
values reached during this period of observation. The maximum values were as
follows: (A) for skin lesions: 40% of total body surface area at M11 a.p.
(evaluated prospectively by the palm of the hand method; Agarwal and Sahu,
2010); (B) for TCDD in serum: 890 pg/g wet weight (ww) at M3 a.p.; (C) for
TCDD in skin lesions: 5000 pg/g ww at M11 a.p. At that time, TCDD
concentration in skin lesions was therefore 10-fold that of serum. This indicates
that the skin lesions do constitute a significant novel compartment, which could
have reached 6400 cm3 for the entire body by M11 a.p., containing about 35 lg
TCDD, i.e., 2% of the total initial body burden (see Fig. 5 and discussion).
FIG. 5. Volumetric analyses of the skin lesions. (A) Three-dimensional
representation of the calculated total skin volume of the face using the
methodology described in the text. (B) Three-dimensional representation of the
calculated volume of the hamartomatous lesions seen in the same area as in (A).
Anterior view. Note that most lesions are located in the ear lobes and lateral
cheeks. (C) Thick slab reconstruction of an FDG PET data set obtained from
a whole-body PET/CT acquisition showing the distribution and the metabolism
of the skin lesions on the back of the patient. Posterior view. Note that some
lesions display a high metabolism (major FDG uptake, dark spots), whereas
other lesions are metabolically less active (moderate FDG uptake, gray spots).
‘‘Metabolism’’ refers to FDG uptake, most probably linked to secondary
inflammation rather than to CYP1A1/dioxin metabolism.
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The M10 (M24th to M34th a.p.) during which adalimumab blood
concentration was maintained at around 10 lg/ml (i.e., 80 mg every
other week) corresponded to a progressive but very significant
response on the inflammatory component. Generation of new
hamartomatous lesions abruptly declined from month 28, but the
extent to which this improvement was driven by TNF-a blockade
versus the repeated interventional treatment is currently unclear.
Moreover, we are aware that no conclusion may be extrapolated
about therapeutic results from a single case.
DISCUSSION
This case being historically the one in whom the highest ever
number of skin specimens have been obtained in a prospective
context over four years, the data strongly support the previously
proposed idea that sebaceous gland atrophy might be a major
feature of dioxin toxicity (Panteleyev et al., 1997; Suskind,
1985). In parallel to the observed atrophy of sebaceous glands,
several genes encoding for key sebaceous lipid synthesis
enzymes were strongly repressed. Because we identified AhR-
responsive elements in the promoters of many of these genes,
dioxin-induced transcriptional repression of lipid metabolism
may be one mechanism driving the atrophy of sebaceous glands.
This would also be consistent with the reported negative effect
of AhR signaling in adipogenesis (Shimba et al., 2003).
No specific characteristics had previously been shown to
distinguish dioxin-induced skin lesions from those seen in
nodulocystic acne or hidradenitis suppurativa (Plewig and
Kligman, 1993). In this study, two distinct pathological signs
were consistently identified in the patient’s skin: one was
a mantle-like outgrowth and the other a reproducible strong focal
expression of CYP1A1 in the cyst cell wall. The ‘‘mantle’’ is
thought to be an early stage in the formation of the sebaceous
gland during the so-called sebaceous gland cycle (de Viragh,
1995). The ontogeny of the dioxin-induced hamartomas might
therefore imply reprogramming of the sebaceous gland cycle,
where sebaceous differentiation is replaced by a vigorous
hamartomatous growth, driven by the dioxin-redistributed
growth factors milieu. Transcriptomics in this case pointed to
a very compatible pathway, the bone morphogenetic proteins
and its antagonists: bone morphogenetic proteins are members of
the transforming growth factor-beta family that has a role in
proliferation, apoptosis, and differentiation in various tissues and
organs, including skin. BMP signaling has been shown to be
necessary for maintaining quiescence of adult epidermal stem cells,
and it is likely that BMP signaling acts through other pathways in
regulating quiescence and proliferation (Kangsamaksin and
Morris, 2011; Sneddon et al., 2006). This needs to be
specifically explored, with appropriate experimental models,
for deciphering the mechanisms of such morphogenetic
properties of dioxin in skin and potentially in other organs.
The strong expression of CYP1A1 protein in the hamartoma
cell wall but not in the adjacent skin epithelia, as detected by
immunohistochemistry, matches the strong CYP1A1 gene
induction found in tissue. It appears to be a candidate new
marker of dioxin-induced skin pathology; thus, the striking
picture shown in Figure 3C (1) was seen in all biopsy
specimens from the patient, (2) was absent in a panel of skin
cysts including hidradenitis suppurativa (not shown), (3) was
found in patients of a recent chloracne outbreak in Italy
(Passarini et al., 2010) (not shown), and more importantly (4)
we could observe a sticking identical picture in archival skin
specimens from the only previous human case with a similar
high level of dioxin exposure, published by Geusau et al.
(1999) (not shown, see acknowledgments).
In addition to its potential diagnostic interest, there are two
further implications of the strong focal expression of CYP1A1
in the hamartomas.
First, the CYP1A1 may have role in the skin pathology.
CYP1A1 expression has been correlated to TCDD toxicity in
various in vitro and animal models (Rifkind, 2006). In
particular, arachidonate, the gene pathway metabolism of
which was associated to the most differently expressed in the
skin of our patient, is a substrate for CYP1A1 and even more
CYP1A2. Therefore, bioactive arachidonate derivatives could
be involved in some TCDD effects (Rifkind, 2006).
Second, skin-expressed CYP1A1 may itself play a direct role
in the phase I metabolism of dioxin, which we have recently
characterized for the first time in humans (Sorg et al., 2009).
The amount of CYP1A1 protein available through a multitude
of skin hamartomas represents a potentially significant source of
enzymatic activity, which may add to the xenobiotic metabo-
lism potential of the classical organs such as the liver.
The skin lesions historically called chloracne therefore
represent a functional hamartomatous adaptive process to this
poison exposure. We have suggested they would better be called
‘‘metabolizing acquired dioxin-induced skin hamartomas’’ (Saurat
and Sorg, 2010). Such an adaptive response points to the potential
role of the skin in the metabolism of orally introduced
xenobiotics, other than dioxin, as well (Rowe et al., 2008).
FUNDING
Swiss Center for Applied Human Toxicology and Derma-
tology Fund University of Geneva (UF1024).
ACKNOWLEDGMENTS
Marion Bonna is acknowledged for her invaluable contri-
bution to the administrative management of the case. R.
Fedosyuk, R. Valikhnovskyi, V. Kniazevych, O. Gaide, M.
Harms, D. Salomon, A. Skaria, C. Tschanz, A. M. Thielen, and
G. Marrazza are acknowledged for their most significant
contribution to the medical team involved in the patient care.
Many consultants from our institution, University Hospital of
Geneva, Faculty of Medicine of Geneva, as well from other
316 SAURAT ET AL.
countries around the world provided help and advice at all
stages of the project; each will be specifically cited and
acknowledged in further relevant publications. Alexandra
Geusau, Vienna, is warmly acknowledged for providing skin
specimens from her historical case for CYP1A1 staining. We
thank M. Jorge Remunian for his valuable help with the
volume calculations and Oliver Hartley for kindly reviewing
the manuscript. Author contribution: J.H.S. and O.S. designed
the study and wrote the manuscript; G.K., N.S., L.F., F.M.,
P.C., C.P., C.B., and F.F. performed and analyzed histological
analyses; M.Z. and P.S. determined dioxin concentrations; and
O.S. and P.D. performed genomic analyses. The authors have
no competing interests to declare.
REFERENCES
Agarwal, P., and Sahu, S. (2010). Determination of hand and palm area as
a ratio of body surface area in Indian population. Indian J. Plast. Surg. 43,
49–53.
Albrecht, E. (1904). U¨ber hamartome. Dtsch. Ges. Pathol. 7, 153–157.
Aylward, L. L., Lamb, J. C., and Lewis, S. C. (2005). Issues in risk assessment
for developmental effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related
compounds. Toxicol. Sci. 87, 3–10.
Barouti, N., Fontao, L., Pardo, B., Sorg, O., and Saurat, J. H. (2009). AhR
pathway as a novel pharmacological target for wound healing. J. Invest.
Dermatol. 129, S80.
Brembilla, N. C., Ramirez, J. M., Chicheportiche, R., Sorg, O., Saurat, J. H.,
and Chizzolini, C. (2011). In vivo dioxin favors interleukin-22 production by
human CD4þ T cells in an aryl hydrocarbon receptor (AhR)-dependent
manner. PLoS One 6, e18741.
Caputo, R., Monti, M., Ermacora, E., Carminati, G., Gelmetti, C., Gianotti, R.,
Gianni, E., and Puccinelli, V. (1988). Cutaneous manifestations of
tetrachlorodibenzo-p-dioxin in children and adolescents. Follow-up 10 years
after the Seveso, Italy, accident. J. Am. Acad. Dermatol. 19, 812–819.
Cartharius, K., Frech, K., Grote, K., Klocke, B., Haltmeier, M.,
Klingenhoff, A., Frisch, M., Bayerlein, M., and Werner, T. (2005).
MatInspector and beyond: Promoter analysis based on transcription factor
binding sites. Bioinformatics 21, 2933–2942.
Connor, K. T., Harris, M. A., Edwards, M. R., Budinsky, R. A., Clark, G. C.,
Chu, A. C., Finley, B. L., and Rowlands, J. C. (2008). AH receptor agonist
activity in human blood measured with a cell-based bioassay: Evidence for
naturally occurring AH receptor ligands in vivo. J. Expo. Sci. Environ.
Epidemiol. 18, 369–380.
de Viragh, P. A. (1995). The ‘mantle hair of Pinkus.’ A review on the occasion
of its centennial. Dermatology 191, 82–87.
Fujita, P. A., Rhead, B., Zweig, A. S., Hinrichs, A. S., Karolchik, D.,
Cline, M. S., Goldman, M., Barber, G. P., Clawson, H., Coelho, A., et al.
(2010). The UCSC Genome Browser database: Update 2011. Nucleic Acids
Res. 39, D876–D882.
Geusau, A., Tschachler, E., Meixner, M., Sandermann, S., Pa¨pke, O., Wolf, C.,
Valic, E., Stingl, G., and McLachlan, M. (1999). Olestra increases faecal
excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Lancet 354, 1266–1267.
Gies, A., Neumeier, G., Rappolder, M., and Konietzka, R. (2007). Risk
assessment of dioxins and dioxin-like PCBs in food—Comments by the
German Federal Environmental Agency. Chemosphere 67, S344–S349.
IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. (1997).
Polychlorinated Dibenzo-Para-Dioxins and Polychlorinated Dibenzofurans,
pp. 33–343. IARC, Lyon, France.
Kangsamaksin, T., and Morris, R. J. (2011). Bone morphogenetic protein 5
regulates the number of keratinocyte stem cells from the skin of mice.
J. Invest. Dermatol. 131, 580–585.
Lebeau, S., Masouye´, I., Berti, M., Augsburger, E., Saurat, J. H., Borradori, L.,
and Fontao, L. (2005). Comparative analysis of the expression of ERBIN and
Erb-B2 in normal human skin and cutaneous carcinomas. Br. J. Dermatol.
152, 1248–1255.
Marshall, N. B., and Kerkvliet, N. I. (2010). Dioxin and immune regulation:
Emerging role of aryl hydrocarbon receptor in the generation of regulatory T
cells. Ann. N. Y. Acad. Sci. 1183, 25–37.
Montagna, W. (1963). In The Sebaceous Glands (W. Montagna, R. A. Ellis and
A.F. Silver, Eds.), pp. 167–187. Pergamon Press, Oxford, U.K.
Panteleyev, A. A., Thiel, R., Wanner, R., Zhang, J., Roumak, V. S., Paus, R.,
Neubert, D., Henz, B. M., and Rosenbach, T. (1997). 2,3,7,8-Tetrachloro-
dibenzo-p-dioxin (TCCD) affects keratin 1 and keratin 17 gene expression and
differentially induces keratinization in hairless mouse skin. J. Invest. Dermatol.
108, 330–335.
Passarini, B., Infusino, S. D., and Kasapi, E. (2010). Chloracne: Still cause for
concern. Dermatology 221, 63–70.
Plewig, G., and Kligman, A. M. (1993). In Acne and Rosacea. Springer-Verlag,
Berlin, Germany.
Ramirez, J. M., Brembilla, N. C., Sorg, O., Chicheportiche, R., Matthes, T.,
Dayer, J. M., Saurat, J. H., Roosnek, E., and Chizzolini, C. (2010). Activation
of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and
IL-17 production by human T helper cells. Eur. J. Immunol. 40, 2450–2459.
Rifkind, A. B. (2006). CYP1A in TCDD toxicity and in physiology—With
particular reference to CYP dependent arachidonic acid metabolism and
other endogenous substrates. Drug Metab. Rev. 38, 291–335.
Rowe, J. M., Welsh, C., Pena, R. N., Wolf, C. R., Brown, K., and
Whitelaw, C. B. (2008). Illuminating role of CYP1A1 in skin function.
J. Invest. Dermatol. 128, 1866–1868.
Ryan, J. J. (2011). In The Yushchenko Dioxin Poisoning: Chronology and
Pharmacokinetics. Wiley, Hoboken, NJ.
Saurat, J. H., and Sorg, O. (2010). Chloracne, a misnomer and its implications.
Dermatology 221, 23–26.
Schecter, A. J., Sheu, S. U., Birnbaum, L. S., DeVito, M. J., Denison, M. S.,
and Pa¨pke, O. (1999). A comparison and discussion of two different methods
of measuring dioxin-like compounds: Gas chromatography–mass spectrom-
etry and the CALUX bioassay F implications for health studies. Organohal.
Compounds 40, 247–250.
Shimba, S., Hayashi, M., Ohno, T., and Tezuka, M. (2003). Transcriptional
regulation of the AhR gene during adipose differentiation. Biol. Pharm. Bull.
26, 1266–1271.
Sneddon, J. B., Zhen, H. H., Montgomery, K., van de Rijn, M., Tward, A. D.,
West, R., Gladstone, H., Chang, H. Y., Morganroth, G. S., Oro, A. E., et al.
(2006). Bone morphogenetic protein antagonist gremlin 1 is widely
expressed by cancer-associated stromal cells and can promote tumor cell
proliferation. Proc. Natl. Acad. Sci. U.S.A. 103, 14842–14847.
Sorg, O., Tran, C., Carraux, P., Grand, D., Barraclough, C., Arrighi, J. F.,
Descombes, P., Piguet, V., and Saurat, J. H. (2008). Metabolism and
biological activities of topical 4-oxoretinoids in mouse skin. J. Invest.
Dermatol. 128, 999–1008.
Sorg, O., Zennegg, M., Schmid, P., Fedosyuk, R., Valikhnovskyi, R.,
Gaide, O., Kniazevych, V., and Saurat, J. H. (2009). 2,3,7,8-Tetrachloro-
dibenzo-p-dioxin (TCDD) poisoning in Victor Yushchenko: Identification
and measurement of TCDD metabolites. Lancet 374, 1179–1185.
Steenland, K., Deddens, J., and Piacitelli, L. (2001). Risk assessment for
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) based on an epidemiologic
study. Am. J. Epidemiol. 154, 451–458.
Suskind, R. R. (1985). Chloracne, ‘‘the hallmark of dioxin intoxication.’’
Scand. J. Work Environ. Health 11, 165–171.
LESSONS FROM THE POISONING OF VICTOR YUSHCHENKO 317
